On the stock market since 2024, it operates in the world of health and science. It has 327 employees. Now — the numbers.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash-and-debt balance is neither shiny nor alarming.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
The stock has been running stronger than the market lately.
Business Quality: Profit power and business quality trail similar companies in the sector.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Executive Buying: The trades send no strong signal of confidence.
The stock trades 18% below its peak. The market has trimmed its expectations for the company.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 38/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 45/100.
No clear buy-side message is coming from the executive floor. Council score: 3/10.
On our five-subject report card, CBLL sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CBLL is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.